Article summary
Recent reporting, has documented a string of serious adverse events at overseas psychedelic clinics such as cardiac deaths, treatment-related fatalities, and patients who were never adequately screened for the health conditions that make ibogaine dangerous in the first place. There's no central registry tracking these outcomes, which means the industry is operating with an incomplete picture of its own risk profile. What reporting has surfaced is enough to suggest the problem isn't rare or isolated: inconsistent medical screening, staff distributing medications without regard to a patient's history, and facilities operating with little external oversight. The post Ibogaine’s Momentum Is Real. So Is the Safety Gap Nobody’s Solving. appeared first on Microdose.
Continue to the original publication for the complete article.